PriceTargets.com logo

Odyssey Therapeutics - ODTX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $35.33
  • Forecasted Upside: 101.10%
  • Number of Analysts: 10
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 7 Buy Ratings
  • 1 Strong Buy Ratings
$17.57 As of 10/15/2026 05:00 PM ET
▲ +0.97 (5.84%)

This chart shows the closing price for ODTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Odyssey Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ODTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ODTX

Analyst Price Target is $35.33
▲ +101.10% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Odyssey Therapeutics in the last 3 months. The average price target is $35.33, with a high forecast of $44.00 and a low forecast of $27.00. The average price target represents a 101.10% upside from the last price of $17.57.

This chart shows the closing price for ODTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 10 polled investment analysts is to moderate buy stock in Odyssey Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/22/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/20/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/18/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/18/2026
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/17/2026
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/15/2026
  • 1 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
10/15/2026

Latest Recommendations

  • 1 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/12/2026UBS GroupInitiated CoverageBuy$27.00
10/12/2026UBS GroupUpgradeStrong-Buy
10/8/2026Raymond James FinancialInitiated CoverageOutperform$42.00
10/8/2026Raymond James FinancialInitiated CoverageOutperform$42.00
8/27/2026HC WainwrightInitiated CoverageBuy$44.00
8/27/2026HC WainwrightInitiated CoverageBuy$44.00
8/11/2026Weiss RatingsInitiated CoverageSell (D+)
8/7/2026JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$26.00 ➝ $29.00
6/18/2026OppenheimerReiterated RatingOutperform ➝ Outperform$40.00
6/3/2026Zacks ResearchUpgradeHold
6/2/2026Cantor FitzgeraldInitiated CoverageOverweight
6/2/2026TD CowenInitiated CoverageBuy
6/2/2026JPMorgan Chase & Co.Initiated CoverageOverweight$26.00
6/2/2026WedbushInitiated CoverageOutperform$30.00
6/2/2026OppenheimerInitiated CoverageOutperform$40.00
(Data available from 10/15/2021 forward)

News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2026
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/18/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/17/2026
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/17/2026
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/16/2026
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/15/2026
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/15/2026

Current Sentiment

  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Odyssey Therapeutics

Odyssey Therapeutics Inc. is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc. is based in BOSTON.
Read More

Today's Range

Now: $17.57
Low: $16.36
High: $17.75

50 Day Range

MA: $22.54
Low: $16.60
High: $28.76

52 Week Range

Now: $17.57
Low: $15.10
High: $29.05

Volume

159,038 shs

Average Volume

301,897 shs

Market Capitalization

$844.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Odyssey Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Odyssey Therapeutics in the last twelve months: Cantor Fitzgerald, HC Wainwright, JPMorgan Chase & Co., Oppenheimer Holdings, Inc., Raymond James Financial, Inc., TD Cowen, UBS Group AG, Wall Street Zen, Wedbush, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for ODTX.

What is the current price target for Odyssey Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Odyssey Therapeutics in the last year. Their average twelve-month price target is $35.33, suggesting a possible upside of 101.1%. HC Wainwright has the highest price target set, predicting ODTX will reach $44.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $27.00 for Odyssey Therapeutics in the next year.
View the latest price targets for ODTX.

What is the current consensus analyst rating for Odyssey Therapeutics?

Odyssey Therapeutics currently has 1 sell rating, 1 hold rating, 7 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ODTX.

What other companies compete with Odyssey Therapeutics?

Other companies that are similar to Odyssey Therapeutics include Veracyte, Legend Biotech, Viking Therapeutics, Xenon Pharmaceuticals and ACADIA Pharmaceuticals. Learn More about companies similar to Odyssey Therapeutics.

How do I contact Odyssey Therapeutics' investor relations team?

Odyssey Therapeutics' physical mailing address is 51 Sleeper Street, Boston, MA, 02210. The company's listed phone number is 617-865-9628 and its investor relations email address is [email protected]. The official website for Odyssey Therapeutics is odysseytx.com. Learn More about contacing Odyssey Therapeutics investor relations.